TY - JOUR
T1 - NAT8 variants, N-acetylated amino acids, and progression of CKD
AU - Luo, Shengyuan
AU - Surapaneni, Aditya
AU - Zheng, Zihe
AU - Rhee, Eugene P.
AU - Coresh, Josef
AU - Hung, Adriana M.
AU - Nadkarni, Girish N.
AU - Yu, Bing
AU - Boerwinkle, Eric
AU - Tin, Adrienne
AU - Arking, Dan E.
AU - Steinbrenner, Inga
AU - Schlosser, Pascal
AU - Köttgen, Anna
AU - Grams, Morgan E.
N1 - Publisher Copyright:
© 2021 by the American Society of Nephrology.
PY - 2021/1
Y1 - 2021/1
N2 - Background and objectives Genetic variants in NAT8, a liver-and kidney-specific acetyltransferase encoding gene, have been associated with eGFR and CKD in European populations. Higher circulating levels of two NAT8-associated metabolites, N-d-acetylornithine and N-acetyl-1-methylhistidine, have been linked to lower eGFR and higher risk of incident CKD in the Black population. We aimed to expand upon prior studies to investigate associations between rs13538, a missense variant in NAT8, N-acetylated amino acids, and kidney failure in multiple, well-characterized cohorts. Design, setting, participants, & measurements We conducted analyses among participants with genetic and/or serum metabolomic data in the African American Study of Kidney Disease and Hypertension (AASK; n=962), the Atherosclerosis Risk in Communities (ARIC) study (n=1050), and BioMe, an electronic health record–linked biorepository (n=680). Separately, we evaluated associations between rs13538, urinary N-acetylated amino acids, and kidney failure in participants in the German CKD (GCKD) study (n=1624). Results Of 31 N-acetylated amino acids evaluated, the circulatingand urinarylevels of 14 were associated withrs13538 (P<0.05/31). Higher circulating levels of five of these N-acetylated amino acids, namely, N-d-acetylornithine, N-acetyl-1-methylhistidine, N-acetyl-3-methylhistidine, N-acetylhistidine, and N2,N5-diacetylornithine, were associated with kidney failure, after adjustment for confounders and combining results in meta-analysis (combined hazard ratios per two-fold higher amino acid levels: 1.48, 1.44, 1.21, 1.65, and 1.41, respectively; 95% confidence intervals: 1.21 to 1.81, 1.22 to 1.70, 1.08 to 1.37, 1.29 to 2.10, and 1.17 to 1.71, respectively; all P values <0.05/14). None of the urinary levels of these N-acetylated amino acids were associated with kidney failure in the GCKD study. Conclusions We demonstrate significant associations between an NAT8 gene variant and 14 N-acetylated amino acids, five of which had circulation levels that were associated with kidney failure.
AB - Background and objectives Genetic variants in NAT8, a liver-and kidney-specific acetyltransferase encoding gene, have been associated with eGFR and CKD in European populations. Higher circulating levels of two NAT8-associated metabolites, N-d-acetylornithine and N-acetyl-1-methylhistidine, have been linked to lower eGFR and higher risk of incident CKD in the Black population. We aimed to expand upon prior studies to investigate associations between rs13538, a missense variant in NAT8, N-acetylated amino acids, and kidney failure in multiple, well-characterized cohorts. Design, setting, participants, & measurements We conducted analyses among participants with genetic and/or serum metabolomic data in the African American Study of Kidney Disease and Hypertension (AASK; n=962), the Atherosclerosis Risk in Communities (ARIC) study (n=1050), and BioMe, an electronic health record–linked biorepository (n=680). Separately, we evaluated associations between rs13538, urinary N-acetylated amino acids, and kidney failure in participants in the German CKD (GCKD) study (n=1624). Results Of 31 N-acetylated amino acids evaluated, the circulatingand urinarylevels of 14 were associated withrs13538 (P<0.05/31). Higher circulating levels of five of these N-acetylated amino acids, namely, N-d-acetylornithine, N-acetyl-1-methylhistidine, N-acetyl-3-methylhistidine, N-acetylhistidine, and N2,N5-diacetylornithine, were associated with kidney failure, after adjustment for confounders and combining results in meta-analysis (combined hazard ratios per two-fold higher amino acid levels: 1.48, 1.44, 1.21, 1.65, and 1.41, respectively; 95% confidence intervals: 1.21 to 1.81, 1.22 to 1.70, 1.08 to 1.37, 1.29 to 2.10, and 1.17 to 1.71, respectively; all P values <0.05/14). None of the urinary levels of these N-acetylated amino acids were associated with kidney failure in the GCKD study. Conclusions We demonstrate significant associations between an NAT8 gene variant and 14 N-acetylated amino acids, five of which had circulation levels that were associated with kidney failure.
UR - http://www.scopus.com/inward/record.url?scp=85099533172&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099533172&partnerID=8YFLogxK
U2 - 10.2215/CJN.08600520
DO - 10.2215/CJN.08600520
M3 - Article
C2 - 33380473
AN - SCOPUS:85099533172
SN - 1555-9041
VL - 16
SP - 37
EP - 47
JO - Clinical journal of the American Society of Nephrology : CJASN
JF - Clinical journal of the American Society of Nephrology : CJASN
IS - 1
ER -